Pibrentasvir

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Pibrentasvir
Pibrentasvir.svg
Clinical data
Trade namesMavyret, Maviret (combination with glecaprevir)
SynonymsABT-530
Pharmacokinetic data
Protein binding>99.9%
Elimination half-life13 hours
Excretion96.6% in faeces
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC57H65F5N10O8
Molar mass1113.201 g·mol−1
3D model (JSmol)

Pibrentasvir is an NS5A inhibitor antiviral agent.[1] In the United States and Europe, it is approved for use with glecaprevir as the combination drug glecaprevir/pibrentasvir (trade name Mavyret in the US and Maviret in the EU) for the treatment of hepatitis C.[2][3] It is sold by Abbvie.

References[edit]

  1. ^ Ng, Teresa I.; Krishnan, Preethi; Pilot-Matias, Tami; Kati, Warren; Schnell, Gretja; Beyer, Jill; Reisch, Thomas; Lu, Liangjun; Dekhtyar, Tatyana; Irvin, Michelle; Tripathi, Rakesh; Maring, Clarence; Randolph, John T.; Wagner, Rolf; Collins, Christine (2017). "In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir". Antimicrobial Agents and Chemotherapy. 61 (5): e02558–16. doi:10.1128/AAC.02558-16. PMC 5404558. PMID 28193664.
  2. ^ Linda A. Johnson (August 3, 2017). "FDA OKs new drug to treat all forms of hepatitis C". Fox Business.
  3. ^ "Maviret: EPAR – Summary for the public" (PDF). European Medicines Agency. 2017-08-17.